Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:AXSM NASDAQ:BBIO NASDAQ:CPRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$218.06+1.1%$232.15$160.86▼$250.74$13.45B0.39546,697 shs405,008 shsAXSMAxsome Therapeutics$255.17+0.6%$210.94$96.09▼$257.92$13.06B0.61636,861 shs441,648 shsBBIOBridgeBio Pharma$66.80-1.1%$70.38$38.57▼$84.94$13.23B0.972.71 million shs1.55 million shsCPRXCatalyst Pharmaceuticals$31.360.0%$29.16$19.05▼$32.56$3.84B0.741.92 million shs826,614 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+2.77%-1.48%-9.28%-4.59%+25.55%AXSMAxsome Therapeutics+3.02%+9.63%+13.28%+62.59%+134.80%BBIOBridgeBio Pharma+0.22%+0.33%+2.43%-2.68%+72.98%CPRXCatalyst Pharmaceuticals+0.10%+0.26%+0.74%+35.04%+23.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$218.06+1.1%$232.15$160.86▼$250.74$13.45B0.39546,697 shs405,008 shsAXSMAxsome Therapeutics$255.17+0.6%$210.94$96.09▼$257.92$13.06B0.61636,861 shs441,648 shsBBIOBridgeBio Pharma$66.80-1.1%$70.38$38.57▼$84.94$13.23B0.972.71 million shs1.55 million shsCPRXCatalyst Pharmaceuticals$31.360.0%$29.16$19.05▼$32.56$3.84B0.741.92 million shs826,614 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+2.77%-1.48%-9.28%-4.59%+25.55%AXSMAxsome Therapeutics+3.02%+9.63%+13.28%+62.59%+134.80%BBIOBridgeBio Pharma+0.22%+0.33%+2.43%-2.68%+72.98%CPRXCatalyst Pharmaceuticals+0.10%+0.26%+0.74%+35.04%+23.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$295.3935.46% UpsideAXSMAxsome Therapeutics 2.95Moderate Buy$256.790.63% UpsideBBIOBridgeBio Pharma 2.85Moderate Buy$89.5934.12% UpsideCPRXCatalyst Pharmaceuticals 2.56Moderate Buy$32.002.04% UpsideCurrent Analyst Ratings BreakdownLatest CPRX, BBIO, ASND, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026AXSMAxsome Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$380.006/11/2026AXSMAxsome Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeReduce ➝ Overweight6/9/2026ASNDAscendis Pharma A/S OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/4/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026CPRXCatalyst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)6/3/2026BBIOBridgeBio Pharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$104.005/28/2026CPRXCatalyst Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/28/2026BBIOBridgeBio Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$94.00 ➝ $98.005/28/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$110.005/26/2026BBIOBridgeBio Pharma Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/19/2026BBIOBridgeBio Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$82.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$814.57M16.70N/AN/A($2.97) per share-73.42AXSMAxsome Therapeutics$638.50M20.57N/AN/A$1.75 per share145.81BBIOBridgeBio Pharma$502.08M26.06N/AN/A($10.77) per share-6.20CPRXCatalyst Pharmaceuticals$588.99M6.52$2.92 per share10.73$7.76 per share4.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6725.1520.30N/A57.87%N/A-8.37%8/6/2026 (Estimated)AXSMAxsome Therapeutics-$183.17M-$3.73N/A50.93N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A290.43N/A-124.42%N/A-65.81%8/4/2026 (Estimated)CPRXCatalyst Pharmaceuticals$214.33M$1.7418.0210.180.9537.08%35.76%31.31%8/5/2026 (Estimated)Latest CPRX, BBIO, ASND, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72AXSMAxsome Therapeutics2.271.391.32BBIOBridgeBio PharmaN/A1.521.48CPRXCatalyst PharmaceuticalsN/A7.106.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AAXSMAxsome Therapeutics81.49%BBIOBridgeBio Pharma99.85%CPRXCatalyst Pharmaceuticals79.22%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%AXSMAxsome Therapeutics20.60%BBIOBridgeBio Pharma14.23%CPRXCatalyst Pharmaceuticals10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableCPRXCatalyst Pharmaceuticals80122.42 million109.69 millionOptionableCPRX, BBIO, ASND, and AXSM HeadlinesRecent News About These CompaniesCatalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?June 10 at 12:31 PM | zacks.comWhy Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-TermMay 27, 2026 | zacks.comWhy Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-TermMay 25, 2026 | zacks.comAngelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals StoryMay 20, 2026 | finance.yahoo.comCPRX or UTHR: Which Is the Better Value Stock Right Now?May 14, 2026 | zacks.comCatalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better StoryMay 13, 2026 | seekingalpha.comCatalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/YMay 12, 2026 | zacks.comAre CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?May 12, 2026 | prnewswire.comCatalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 11, 2026 | zacks.comCatalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue EstimatesMay 11, 2026 | zacks.comCatalyst Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 11, 2026 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)May 11, 2026 | globenewswire.comCatalyst Pharmaceuticals Buyout And FIRDAPSE Patents Reframe Investor OutlookMay 10, 2026 | finance.yahoo.comCatalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRXMay 9, 2026 | businesswire.comCitigroup downgrades Catalyst Pharmaceuticals (CPRX)May 9, 2026 | msn.comStephens & Co. downgrades Catalyst Pharmaceuticals (CPRX)May 8, 2026 | msn.comCatalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and WebcastMay 8, 2026 | markets.businessinsider.comAngelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare ...May 7, 2026 | markets.businessinsider.comAngelini Pharma to buy Catalyst Pharmaceuticals for $4.1BMay 7, 2026 | seekingalpha.comSeeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key MetricsMay 7, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPRX, BBIO, ASND, and AXSM Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$218.06 +2.46 (+1.14%) Closing price 04:00 PM EasternExtended Trading$218.30 +0.24 (+0.11%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Axsome Therapeutics NASDAQ:AXSM$255.17 +1.40 (+0.55%) Closing price 04:00 PM EasternExtended Trading$259.93 +4.76 (+1.87%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.BridgeBio Pharma NASDAQ:BBIO$66.80 -0.75 (-1.11%) Closing price 04:00 PM EasternExtended Trading$66.81 +0.01 (+0.01%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Catalyst Pharmaceuticals NASDAQ:CPRX$31.36 -0.01 (-0.03%) Closing price 04:00 PM EasternExtended Trading$31.20 -0.16 (-0.53%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
